Physician profile
Dwayne Watkins
NPI 1174543276
$8,215.75
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $7,993 · 2021: $63.51 · 2022: $51.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $7,956.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.35 | 2021-2022 | |
| Novo Nordisk INC | $44.17 | 2019 | |
| Kvk-Tech, INC. | $44.10 | 2019 | |
| Lilly USA, LLC | $36.61 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $20.70 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.82 | 2019 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwayne Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.